Stratasys completes US rollout of 3D-printed imaging support material
Stratasys’3D printed RadioMatrix technology is now fully available in the US, offering clinicians a platform to create radio-realistic models.
Made of a material called radiopaque, RadioMatrix is claimed to be the first 3D printed material that delivers control over radiopacity. This enables clinicians can produce patient-specific models with ‘fully tuneable’ visibility on X-ray-based imaging.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Applicable for image-based training and surgical planning, 3D printing specialist Stratasys said the material aims to create more controlled, repeatable environments for research.
Stratasys’s healthcare vice-president Erez Ben-Zvi called the full US commercialisation of RadioMatrix a “major step” in advancing imaging education and training.
Ben-Zvi said: “By giving radiologists and device manufacturers the ability to print ultra-realistic, customised radiographically accurate models, we’re helping replace traditional phantom solutions and reliance on cadavers with customisable, repeatable, and scalable alternatives.”
In February 2025, Stratasys and Siemens Healthineers presented data from a collaboration which showed that 3D printed RadioMatrix ‘phantoms’ were able to closely replicate real human tissue in CT imaging, with reported deviations as low as single Hounsfield units (HU) in critical areas such as grey matter and veins.
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe companies’ work found that anatomically realistic, radio-accurate phantoms could preserve fine anatomical details and pathological variations specific to individual patients.
Siemens Healthineers paired its imaging algorithms with Stratasys’ 3D printed material to improve how radiologists validate and optimise CT protocols, along with accelerating the development of new imaging algorithms for more precise diagnosis and treatment planning.
According to GlobalData analysis, the medical 3D printing market is growing at a compound annual growth rate (CAGR) of 21% and is forecast to reach a market valuation of $4bn in 2026, up from $2bn in 2022.
Beyond imaging-related training protocols, in the healthcare space, 3D printing is driving change in the planning of, and assistance during surgical procedures. Research published in Academic Radiology has indicated that the use of 3D anatomic models as surgical guides reduced surgical time by a mean of 62 minutes and resulted in cost savings of $3,720 per case.
In other healthcare segments, Stratasys is involved in a collaboration with CollPlant Biotechnologies to develop 3D-printed breast implants while US-based biotechnology company FluidForm Bio is working to advance 3D-printing of human cardiac tissue using freeform reversible embedding of suspended hydrogels (FRESH) 3D bioprinting.
Sign up for our daily news round-up!
Give your business an edge with our leading industry insights.
Medical Device Network Excellence Awards - The Benefits of Entering
Gain the recognition you deserve! The Medical Device Network Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving medical devices advancements. Don’t miss your chance to stand out—submit your entry today!
Nominate NowContent Original Link:
" target="_blank">
